Yogamet-Trio 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and increasing peripheral insulin sensitivity, contributing to reduced blood glucose levels without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, effectively controlling postprandial hyperglycemia. The sustained-release formulation ensures a gradual and prolonged release of the active ingredients, promoting better patient compliance and stable plasma drug concentrations. Yogamet-Trio 2 Tablet SR is indicated for patients inadequately controlled by diet, exercise, and monotherapy, offering a multifaceted approach to glycemic management by targeting different pathophysiological aspects of diabetes. It should be used under medical supervision with regular monitoring of blood glucose and renal function. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in cases of diabetic ketoacidosis or hypersensitivity to any component. Adverse effects may include gastrointestinal disturbances, hypoglycemia, and rare allergic reactions.